{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:34:26Z","timestamp":1788885266324,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jpeds.2016.07.040","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T23:45:01Z","timestamp":1472168701000},"page":"227-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents"],"prefix":"10.1016","volume":"178","author":[{"given":"Wendy K.M.","family":"Liew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Visyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athos","family":"Bousvaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2016.07.040_bib0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0015","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/tera.1420380303","article-title":"A short history of thalidomide embryopathy","volume":"38","author":"Lenz","year":"1988","journal-title":"Teratology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0025","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM196212062672305","article-title":"The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies","volume":"267","author":"Mellin","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0030","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM196212132672407","article-title":"The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies","volume":"267","author":"Mellin","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0035","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1212\/01.WNL.0000131766.90137.DF","article-title":"Thalidomide neuropathy: too much or too long?","volume":"62","author":"Apfel","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1592\/phco.23.4.481.32115","article-title":"Thalidomide for erythema nodosum leprosum and other applications","volume":"23","author":"Okafor","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0149-2918(03)80085-1","article-title":"Thalidomide: a review of approved and investigational uses","volume":"25","author":"Matthews","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MPG.0b013e318228349e","article-title":"Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab","volume":"54","author":"Felipez","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0065","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3109\/07853890108995961","article-title":"Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature","volume":"33","author":"Ginsburg","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0070","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00005176-200102000-00016","article-title":"Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results","volume":"32","author":"Facchini","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0080","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/rheumatology\/40.8.933","article-title":"Behcet's disease in UK children: clinical features and treatment including thalidomide","volume":"40","author":"Kari","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/01.WNL.0000042321.94839.78","article-title":"Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1","volume":"60","author":"Gupta","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/14740338.3.1.47","article-title":"Thalidomide: an old drug with new clinical applications","volume":"3","author":"Laffitte","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2015.01.002","article-title":"Review of thalidomide use in the pediatric population","volume":"72","author":"Yang","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0733-8635(05)70232-1","article-title":"Thalidomide","volume":"19","author":"Radomsky","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0105","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0110","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","article-title":"Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study","volume":"62","author":"Cavaletti","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nmd.2004.10.005","article-title":"Thalidomide neuropathy in childhood","volume":"15","author":"Fleming","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pediatrneurol.2007.11.004","article-title":"Childhood thalidomide neuropathy: a clinical and neurophysiologic study","volume":"38","author":"Priolo","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0125","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/bmj.2.5256.855","article-title":"Neuropathy after intake of thalidomide (distaval)","volume":"2","author":"Fullerton","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0135","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1212\/01.WNL.0000130499.91775.2C","article-title":"Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus","volume":"62","author":"Briani","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0140","series-title":"The clinical neurophysiology primer","first-page":"369","article-title":"Pediatric nerve conduction studies and EMG","author":"Kang","year":"2007"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0145","series-title":"Electromyography and neuromuscular disorders","author":"Preston","year":"2005"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0150","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/mus.1109","article-title":"Thalidomide neuropathy in patients treated for metastatic prostate cancer","volume":"24","author":"Molloy","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0404.2003.00203.x","article-title":"Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features","volume":"109","author":"Isoardo","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1985.tb02323.x","article-title":"Development of polyneuropathy during thalidomide therapy","volume":"112","author":"Wulff","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients","volume":"130","author":"Ochonisky","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjmed.2004.03.040","article-title":"Adverse effects of thalidomide administration in patients with neoplastic diseases","volume":"117","author":"Dimopoulos","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00192350","article-title":"Thalidomide-induced neuropathy and genetic differences in drug metabolism","volume":"49","author":"Harland","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00313852","article-title":"Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation","volume":"233","author":"Hess","year":"1986","journal-title":"J Neurol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0185","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.31.6.543","article-title":"Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study","volume":"31","author":"Fullerton","year":"1968","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0190","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1212\/01.WNL.0000049462.03800.B1","article-title":"Thalidomide-induced neuropathy: a ganglionopathy?","volume":"60","author":"Giannini","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0195","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jpeds.2016.07.040_bib0200","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.critrevonc.2013.02.001","article-title":"Pomalidomide: new immunomodulatory agent with potent antiproliferative effects","volume":"88","author":"Richardson","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0205","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jns5.12002","article-title":"Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study","volume":"18","author":"Briani","year":"2013","journal-title":"J Peripher Nerv Syst"},{"issue":"suppl 2","key":"10.1016\/j.jpeds.2016.07.040_bib0215","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0305-7372(10)70009-8","article-title":"Management of treatment-related adverse events in patients with multiple myeloma","volume":"36","author":"Mateos","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0220","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3109\/10428194.2013.869329","article-title":"Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis","volume":"55","author":"Zagouri","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jpeds.2016.07.040_bib0225","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347616306424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347616306424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T10:04:43Z","timestamp":1582538683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347616306424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":44,"alternative-id":["S0022347616306424"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2016.07.040","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2016.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}